322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

STAT reporter Matt Herper joins us to break down all the angles of this week's tumultuous week in cancer immunotherapy, including his up-close look at Summit co-CEO Bob Duggan. We also discuss the latest news in the life sciences, including Moderna pruning its pipeline and its spending, plus results from a study that tested a GLP-1 drug in children.

Episode metadata supplied by the publisher feed · Published Sep 12, 2024

Embed this episode

Attribution link and audio player

Ready to play

322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

0:00 32:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 32 minutes long.

When was this The Readout Loud episode published?

This episode was published on September 12, 2024.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!